Grants and Contributions:

Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019).

Analogues of natural products are known to be an abundant reservoir for medicinally relevant compounds, withx000D
many such molecules being commercialized into therapeutically useful drugs, such as cancer therapies.x000D
Historically, considerable effort in the field of organic chemistry has been applied to the development of newx000D
synthetic methods for the construction of these natural products and their respective therapeutically usefulx000D
derivatives. Although many synthetic transformations have been developed, new synthetic methods arex000D
urgently required to make syntheses shorter, safer, greener and more atom economical. It is the goal of thisx000D
research project to resolve problematic process chemistry reactions that have been identified by Dalton Pharmax000D
Services by creating new flow chemistry-based methods that will be used in the synthesis of activex000D
pharmaceutical ingredients (API), which are commonly derivatives of natural products. Specifically, we willx000D
develop new flow-based synthesis protocols for i) reductions using lithium aluminum hydride (LiAlH4) and ii)x000D
reduction of alkynes to alkenes that are suitable for process scale applications. Currently, these types ofx000D
reactions are particularly problematic to perform on large scale due to safety and reactivity problems that arex000D
inherent to batch chemistry reactions. To solve these issues, we will develop flow chemistry synthetic protocolsx000D
that will replace these current process scale batch methods (vide infra). The field of flow chemistry is poised tox000D
have a transformative effect on the discipline of organic synthesis by avoiding the costly, inefficient methods ofx000D
batch, and replacing them with superior methods that allow for safer, greener and more proficient chemicalx000D
transformations. In its simplest form, flow chemistry replaces conventional fixed-volume batch reaction flasksx000D
with flow microreactors, hence the term "flow" chemistry. This research project plans to utilize the benefits ofx000D
flow chemistry and develop continuous flow processes that will solve the problems that are inherent whenx000D
scaling-up these batch reactions. Overall, resolving the problematic batch reactions that have been identified byx000D
Dalton Pharma Services, and yield much more cost-effective and safer chemical processes.